Who is eligible for clinical trial NCT03022552?

Participants must meet protocol criteria for Myocardial Infarction. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT03022552 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-04-17

Heart Attack Research Program: Platelet Sub-Study (HARP) (NCT03022552)

🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: NYU Langone Health

🩺 Plain-English Summary (8th-Grade Level)

This prospective observational cohort study, will investigate the platelet phenotype, platelet genetic composition, and role of platelets as effector cells in women and men with myocardial infarction (MINOCA or MI-CAD) and controls. This study, which will take place at NYU and Bellevue Medical Center, and participating external sites. May have concurrent enrollment with the HARP Main Imaging (NCT02914483). Additionally, a sex, group of age and race matched disease controls 'CATH-NOCA' composed of women and men with stable angina referred for cardiac catheterization, will be enrolled. Blood obtained during the initial catheterization and 2 months post-MI will be utilized for platelet testing.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (12 items).

Location: NYU Langone Medical Center — New York, New York

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Acute ischemic symptoms compatible with diagnosis of MI, such as chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms
Objective evidence of MI (either or both of the following):
Elevation of troponin to above the laboratory upper limit of normal (ULN)
ST segment elevation of ≥1mm on 2 contiguous ECG leads
Willing to provide informed consent and comply with all aspects of the protocol
Administration of aspirin at least 1 hour before cardiac catheterization
Administration of thienopyridine (e.g., clopidogrel, ticagrelor) at least 1 hour before cardiac catheterization
Women and men with ≥50% of any major epicardial vessel on invasive angiography may participate

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Recent use of vasospastic agents, such as cocaine, triptans, or ergot alkaloids (≤1 month)
Alternate explanation for troponin elevation, such as hypertensive urgency, acute exacerbation of heart failure, chronic elevation due to kidney disease, pulmonary embolism, cardiac trauma
Pregnancy
Thrombolytic therapy for STEMI (qualifying event)
Use of any of the following medications:
Platelet antagonists (except aspirin and thienopyridines) within 7 days
NSAIDs (e.g., ibuprofen, naproxen) within 3 days.
Thrombocytopenia (platelet count \<100,000)
Thrombocytosis (platelet count \>500,000)
Anemia (hemoglobin \<9 mg/dl)
Hemorrhagic diathesis

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

NYU Langone Medical Center — New York, New York

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗